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A dirty little secret
Mycobacterium tuberculosis is a devastat-
ing  pathogen  that  kills  >1.5  million 
people each year, but controlled use of 
its  cell  wall  activates  macrophages  in 
ways that can be harnessed for therapy. 
For example, M. bovis Bacille Calmette-
Guérin (BCG) is one of the most widely 
used  antitumor  adjuvant  therapies  in 
humans.  Injection  of  BCG  into  the 
bladder mediates regression of transi-
tional cell carcinomas by stimulating a 
vigorous local immune response, bath-
ing tumors in cytokines and activated 
immune cells (Brandau and Suttmann, 
2007). Similarly, Freund’s adjuvant, an 
emulsion  of  mycobacterial  cell  wall 
components  in  paraffin  oil,  is  mixed 
with antigens to optimize memory T 
and B cell responses in mice (Freund   
et al., 1948). In 1989, Charles Janeway 
Jr. dubbed the widespread use of Freund’s 
adjuvant “the immunologist’s dirty lit-
tle secret” (Janeway, 1989). This prac-
tice was considered a secret because the 
co-stimulatory properties of adjuvants 
were  overshadowed  by  the  focus  on 
antigen interactions with T and B cell 
receptors. 20 yr later, the role of innate 
receptors in licensing adaptive responses 
is no longer a secret, but Freund’s adju-
vant remains dirty. Freund’s and BCG 
adjuvants contain hundreds of natural 
molecules,  yet  the  particular  compo-
nents  that  mediate  therapeutic  effects 
have not been identified.
Janeway  advocated  systematically 
sorting through the components of em-
pirically discovered adjuvants to identify 
the  individual  stimulatory  molecules 
and their cellular receptors, especially 
those that lead to interleukin-1  (IL-1) 
secretion (Janeway, 1989). For Gram-
negative  bacteria,  lipopolysaccharide 
(LPS) is the most potent cell wall com-
ponent that leads to innate immune ac-
tivation and sepsis (Fig. 1). Discovery 
of the mechanism by which LPS acti-
vates  CD14,  Toll-like  receptor  4 
(TLR4),  and  myeloid  differentiation 
factor 88 (MyD88) represents a major 
advance in understanding Gram-negative 
bacterial  sepsis,  a  cytokine-mediated 
disease. On page 2879 of this issue, 
Ishikawa et al. (2009) identify a ligand-
receptor  interaction  that  plays  a  role   
in  the  characteristic  immune  process   
of  mycobacterial  infection:  granuloma 
formation. Until recently, Mincle was 
an orphan receptor for which ligands 
were  unknown.  Now,  this  lectin  is 
shown to bind and mediate responses 
to an immunodominant glycolipid in 
the  mycobacterial  cell  wall,  TDM   
(Fig. 1). Here, we discuss Mincle as a 
target for rational adjuvant design and 
review TLRs and C-type lectins as two 
major  innate  pathways  for  host  re-
sponse during M. tuberculosis infection.
Cord factor controls inflammation, 
not cording
In search of a bacterial factor that me-
diates  a  characteristic  growth  pattern 
known as cording, Hubert Bloch iso-
lated a glycolipid from the tubercle ba-
cillus  (Bloch,  1950),  the  structure  of 
which was solved as TDM (Fig. 1; Noll 
et al., 1956). Although widely known 
as cord factor, this glycolipid is no lon-
ger believed to be the cause of bacterial 
cording. Instead, TDM has remained 
the focus of sustained research for five 
decades because of its ability to potently 
activate the innate immune system of 
mammals (Hunter et al., 2006). M. tuber-
culosis is encased in an outer membrane 
formed of very long chain -branched, 
-hydroxy fatty acids (Fig. 1). These un-
usual lipids are known as mycolic acids 
because the lipid type is found only in 
mycobacteria and related actinobacte-
ria. Mycolate lipids like TDM are for-
eign molecules and can be considered 
Actinomycetales-specific  biomarkers. The-
refore,  identifying  the  cellular  recep-
tors for TDM might begin to explain 
why mycobacteria, in contrast to many 
other types of bacteria, generate prom-
inent  granulomas  during  natural 
infection.
TDM  strongly  contributes  to  in-
flammation seen in mycobacterial in-
fection. For example, injection of pure 
TDM in mice stimulates the formation 
of lung granulomas (Bekierkunst et al., 
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carbohydrate-binding proteins and would 
be predicted to bind TDM’s trehalose di-
saccharide (Fig. 2).
The case for C-type lectins as TDM 
receptors  was  supported  by  a  study 
earlier  this  year  showing  that  TDM   
signaling  involves  Syk  and  FcR 
(Werninghaus et al., 2009). Deletion of 
Syk or any of its downstream signaling 
proteins (Card9, Bcl10, or Malt1) essen-
tially eliminated measurable responses to 
TDM  by  mouse  macrophages.  Addi-
tionally, testing of Syk-associated pro-
teins showed that the FcR, but not 
DAP12, was necessary for recognition 
of TDM (Fig. 2). Looking further up-
stream for cell surface receptors, it was 
determined  that  one  of  the  FcR- 
associated proteins, Dectin-1, was not 
the putative receptor. The authors pre-
dicted that the TDM responses would 
involve another FcR-associated recep-
tor such as Dectin-2, dendritic cell acti-
vating receptor, or Mincle (Werninghaus 
et al., 2009).
Sorting through cell walls
With  this  information,  it  might  have 
been possible to discover a receptor for 
TDM  by  analyzing  molecules  in  the 
Syk–FcR pathway, but the work re-
ported here instead pursued the identi-
fication of Mincle ligands using reporter 
constructs.  After  demonstrating  that 
Mincle binds to FcR in its transmem-
brane segment (Yamasaki et al., 2008), 
Mincle and FcR were transfected to-
gether with an ITAM-dependent ex-
pression system into lymphoid cells to 
generate a reporter line. Whereas early 
studies of Mincle suggested that it is ac-
tivated  by  Candida  albicans  (Bugarcic   
et al., 2008; Wells et al., 2008) or fungal 
saprophytes  of  the  Malassezia  genus 
(Yamasaki et al., 2009), Ishikawa et al. 
(2009) linked Mincle to M. tuberculosis, 
a pathogen of worldwide importance. 
Following up on this important obser-
vation, the authors used the reporter to 
identify  the  particular  cell  wall  struc-
tures that activate Mincle.
First, a targeted approach was used 
based  on  the  annotation  of  Mincle’s 
carbohydrate recognition domain (CRD; 
Balch et al., 2002) as a mannose-bind-
ing  motif  (Fig.  2).  To  examine  the   
for signaling. TLRs signal through the 
adaptor MyD88. C-type lectins signal 
through adaptors DAP10, DAP12, or 
Fc receptor  chain (FcR), all of which 
bind phosphorylated Syk proteins with 
immunoreceptor tyrosine activation mo-
tifs (ITAMs; Fig. 2). Before the studies of 
Mincle  reported  here,  it  was  suspected 
that either TLRs (Bowdish et al., 2009)   
or  C-type  lectins  (Werninghaus  et  al.,   
2009)  might  be  responsible  for TDM-
  induced activation of macrophages. Either 
receptor family represents a plausible   
candidate  based  on  their  general  pat-
terns of ligand specificity. The TLR2-1 
heterodimer is a lipid binding receptor 
that uses two hydrophobic pockets to 
sequester the hydrophobic triacylation 
units  on  the  N  terminus  of  bacterial 
proteins (Jin et al., 2007). The finding 
that TLR2, in combination with other 
receptors, influences macrophage acti-
vation  by  TDM  raised  the  possibility 
that TLR2 might in some way capture 
the mycolate lipid units (Bowdish et al., 
2009).  In  contrast,  C-type  lectins  are 
1969) and induces a generalized wasting 
that mimics certain features of consump-
tion  in  tuberculosis  patients  (Kato, 
1968; Ryll et al., 2001). Although my-
cobacteria  contain  several  classes  of   
immunostimulants, TDM has been de-
monstrated to be the most potent stim-
ulator  of  IL-1,  TNF,  and  granuloma 
formation  among  the  BCG  cell  wall 
glycolipids (Geisel et al., 2005). After 
early studies showed that natural TDMs 
enhanced  antibody  production  by  B 
cells  (Bekierkunst  et  al.,  1971),  syn-
thetic TDMs with simplified structures 
are being developed as therapeutic adju-
vants (Davidsen et al., 2005). These studies 
provide a strong rationale to understand 
which  receptors  on  macrophages  and 
dendritic cells mediate the response.
Vetting candidate receptors
The most extensively studied innate re-
ceptors for mycobacteria are TLRs and 
C-type lectins. Both cell surface recep-
tor families lack intracellular signaling 
motifs and depend on adaptor proteins 
Figure 1.  Actinobacteria contain a unique outer layer composed of mycolate lipids. One of 
those lipids, TDM, is an immunostimulant whose potency compares to Gram-negative bacterial LPS, 
but the nature of the inflammation triggered by these two molecules differ.JEM VOL. 206, December 21, 2009 2867
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duction. Thus, the discovery of the role 
of the Mincle–FcR–Syk pathway in 
TB  infection  now  provides  a  tool  to 
tease out the separate and interrelated 
roles of C-type lectins and TLRs as two 
dominant pathways in host response to 
mycobacteria.
Mincle opens new adjuvant avenues
Microbial  products  are  typically 
screened for bioactivity at micromolar 
doses, but LPS, TDM, and other natu-
ral molecules are stimulatory at lower, 
nanomolar concentrations. Because even 
trace contaminates in natural products 
can lead to misidentification of bioac-
tive compounds, chemical synthesis is 
typically  necessary  to  validate  ligands 
for sensitive innate receptors. The re-
port by Ishikawa et al. (2009) is convin-
cing because Mincle could be activated 
by a synthetic analogue, trehalose dibe-
henate (TDB). This result also provides 
insight into potential molecular mecha-
nisms  of  activation.  Recognition  of 
TDB by Mincle proves that activation 
does  not  require  the  long,  branched, 
complex  structures  found  in  natural 
mycolic acids. Instead, Mincle binding 
appears to be specific for the ester link-
age of a fatty acid to trehalose (Fig. 2). 
Humans  express  a  functional  Mincle 
orthologue (Arce et al., 2004), so syn-
thetic and simplified trehalose glycolip-
ids  (Davidsen  et  al.,  2005)  might  be 
developed as adjuvants for human use. 
Both TDM and TDB are composed of 
two glucose mycolate units, which are 
mirror images of each other (Fig. 2). 
Each of the glucose mycolate units is a 
potential Mincle epitope. Because TDM 
analogues that lack elements of the sec-
ond unit are not strongly stimulatory, a 
simple, but untested model is that TDM 
serves  as  a  divalent  activator,  which 
cross-links two Mincle receptors. Fur-
ther testing of this model is of clinical 
import because it predicts that TDB-
like molecules with mono- or multiva-
lent  epitopes  might  be  developed  as 
blockers or superagonists of Mincle. It 
would be tremendously satisfying to see 
the  immunologist’s  dirty  little  secret 
cleaned up to exploit a potentially im-
portant  pathway  of  macrophage  and 
dendritic cell activation.
mannose  motifs  also  bind  structurally 
related sugars like glucose.
This unbiased discovery approach is 
less dependent on assumptions, yet it is 
simple  and  effective.  Although  tran-
scriptional profiling has transformed our 
ability  to  investigate  responses  to  de-
fined stimuli, it requires physically ar-
raying libraries on chips and detection 
of individual transcripts. In contrast, all 
microbe-derived  small  molecules  can 
be  rapidly  extracted  and  the  eluent 
loaded onto a matrix to provide a stream 
of compounds that are individually fed 
into  a  biological  testing  system.  This 
global analysis of bacterial extracts pro-
vides  information  about  the  number, 
relative potency, and structural related-
ness of all bioactive compounds in an 
organism (Moody et al., 2004; Geisel   
et al., 2005).
Is Mincle the major pathway?
In  mice,  Mincle  deletion  essentially 
abolishes many aspects of the in vivo 
response  to  purified TDM,  including 
granulomatous  lung  inflammation 
(Ishikawa  et  al.,  2009). Thus,  Mincle 
plays  an  essential  role  in  response  to 
TDM.  However,  mycobacteria  produce 
several classes of immunostimulants, and 
only  further  investigation  will  deter-
mine whether blocking Mincle–TDM 
interactions  also  alters  the  course  of   
mycobacterial infection. M. tuberculosis 
produces several compounds that act in 
parallel via TLR2, TLR9, mannose re-
ceptor,  Dectin-1,  NOD2,  and  other 
receptors. Illustrating the redundant na-
ture of innate response to this pathogen, 
wild-type  and  TLR-deficient  mice 
show only modest differences in out-
comes  of  experimental  infection  (Su   
et  al.,  2005),  despite  the  remarkably 
strong host responses to mycobacterial 
TLR-2 ligands when they are adminis-
tered as individual stimuli. M. tuberculo-
sis is a readily communicable pathogen 
that has infected one third of all hu-
mans, so it is unsurprising that effective 
immunity does not rely on a single re-
ceptor. However, in the current study, 
Ishikawa et al. (2009) found that dual 
deletion  of  Myd88  and  Mincle  path-
ways reduces key aspects of the overall 
immune response, including TNF pro-
contribution  of  mannose  residues  for 
Mincle  activation,  lipids  from  myco-
bacteria  lacking  mannosyl  transferases 
and  mannolipids  were  tested  one  by 
one for Mincle activity. The targeted 
experiments, however, yielded no re-
sults.  Next,  the  authors  undertook  a 
systematic approach whereby all chro-
matographically  separated  cell  wall 
components  were  exposed  to  the  re-
porter line without regard to whether 
their  structures  contained  mannose. 
This approach led to successful identifi-
cation of TDM as the Mincle ligand. 
Thus,  mycobacterial  recognition  by 
Mincle does not depend upon mannose-
containing glycolipids. Although the fi-
nal  answer  awaits  further  quantitative 
structure–function  studies,  the  man-
nose-binding  motif  in  Mincle  likely 
contacts some aspect of the glucose di-
saccharide, trehalose, in TDM (Fig. 2). 
The apparent contradiction is resolved 
by  understanding  that  proteins  with 
Figure 2.  The mycobacterial lipid TDM and 
its synthetic analogue TDB exist as symmet-
ric trehalose glycolipid structures. Their re-
ceptor, Mincle, couples with Syk and the FcR
chain.2868 Cord factor receptor | Matsunaga and Moody
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